Henlius Seeks To Add RA Indication To Chinese Rituximab
HLX01 Biosimilar Was First Approved In China Under New Pathway
Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.
